Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, October 2001, p. 2933-2935, Vol. 45, No. 10
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.10.2933-2935.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Antimicrobial Susceptibilities of Clinical
Desulfovibrio Isolates
A.
Lozniewski,1
R.
Labia,2
X.
Haristoy,1 and
F.
Mory1,*
Laboratoire de Bactériologie,
Hôpital Central, CHU, 54035 Nancy Cedex,1
and CNRS-UBO-MNHN, Unité FRE 2125, 29000 Quimper,2 France
Received 27 November 2000/Returned for modification 3 June
2001/Accepted 19 July 2001
 |
ABSTRACT |
The antimicrobial susceptibilities of 16 clinical isolates of
Desulfovibrio spp. were determined. All or most isolates
were susceptible to imipenem (MIC90 [MIC at which 90% of
the isolates tested were inhibited], 0.5 µg/ml), metronidazole
(MIC90, 0.25 µg/ml), clindamycin (MIC90, 4 µg/ml), and chloramphenicol (MIC90, 16 µg/ml) but were
resistant or intermediate to penicillin G (MIC90, 64 µg/ml), piperacillin (MIC90, 256 µg/ml),
piperacillin-tazobactam (MIC90, 256 µg/ml), cefoxitin
(MIC90, >256 µg/ml), and cefotetan (MIC90,
64 µg/ml). Among isolates with decreased susceptibility to
-lactams (n = 15), only six were
-lactamase
positive and susceptible to amoxicillin-clavulanate and
ticarcillin-clavulanate.
 |
TEXT |
Desulfovibrio spp. belong
to a group of nonsporing, gram-negative, dissimilatory
sulfate-reducing, anaerobic bacteria. These organisms can be isolated
from various environmental sources and from the intestinal tract of
humans and animals. Desulfovibrio spp. have been reported
only infrequently as causes of human infections, including bacteremia
and brain and liver abscesses (4-6, 8, 9). Thus,
published data on the in vitro susceptibilities of these bacteria to
antibiotics are scarce and have always been obtained from a single
isolate (3-6, 8, 9). However, despite the small numbers
of strains tested, resistance to
-lactams and/or ciprofloxacin has
been found. Thus, consistent data regarding the susceptibilities of
Desulfovibrio spp. to antibiotics currently used for
prophylaxis or empirical treatment of anaerobic infections in which
these organisms may be involved are required.
In the present study, we determined the susceptibilities to
-lactams, metronidazole, clindamycin, chloramphenicol, and
ciprofloxacin of 16 strains (D1 to D16) of Desulfovibrio
spp. isolated consecutively from 16 patients hospitalized at the
University Hospital Center of Nancy (Nancy, France) between 1992 and
1999 (blood, n = 3; liver abscess pus, n = 1; intra-abdominal pus, n = 11; brain abscess pus, n
= 1) and of 2 reference strains, D. desulfuricans ATCC 27774 (isolated from sheep rumen) and D. desulfuricans ATCC
29577 (isolated from a tar-sand mixture). Bacteroides
fragilis ATCC 25285 and Bacteroides thetaiotaomicron
ATCC 29741 were included as control organisms. Strains were stored at
80°C in brucella broth supplemented with 15% glycerol prior to assay.
MICs were determined by the agar dilution method on brucella agar (BD
Difco, Le Pont De Claix, France) supplemented with 5% defibrinated
sheep blood, 5 µg of hemin (Sigma, St. Louis, Mo.) per ml, and 1 µg
of vitamin K1 (Sigma) per ml, as recommended for
anaerobic bacteria by the National Committee for Clinical Laboratory
Standards (NCCLS) (7). Antimicrobial agents used were
obtained from their respective manufacturers. Penicillin G,
amoxicillin, ticarcillin, piperacillin, cefoxitin, cefotetan, cefotaxime, imipenem, metronidazole, clindamycin, chloramphenicol, and
ciprofloxacin were tested at concentrations ranging from 0.06 to 256 µg/ml.
-Lactamase inhibitors were tested at fixed concentrations (clavulanate, 2 µg/ml; tazobactam, 4 µg/ml; sulbactam, 8 µg/ml; cloxacillin [class C
-lactamase inhibitor], 10 and 25 µg/ml) in
combination with
-lactams. As recommended for fastidious anaerobic organisms (7), fresh Desulfovibrio cultures
grown for 72 h on supplemented brucella blood agar were suspended
in reduced brucella broth and inoculated onto the test medium
(approximately 105 CFU per spot) with a
multipoint inoculator (Denley, Billingshurst, United Kingdom).
Inoculated plates were then incubated at 35°C in an anaerobic chamber
(Don Whitley Scientific Ltd., Shippley, United Kingdom). MIC results
were read after 48 h of incubation. MICs were defined as the
lowest concentration of each antimicrobial agent used alone or in
combination with a
-lactamase inhibitor and were interpreted in
accordance with the guidelines of the NCCLS (7). To
evaluate the reproducibility of this method for Desulfovibrio spp., three strains (ATCC 29577, D3, and D11)
were independently tested five times for each antimicrobial agent.
-Lactamase production was assessed by the nitrocefin disk method (Céfinase; bioMérieux, Marcy-l'Etoile, France) after
1 h of incubation at 35°C (2). Preliminary studies
(unpublished data) have shown that this method is more sensitive than
the standard method recommended by the manufacturer for the detection
of Desulfovibrio
-lactamase.
All isolates were susceptible to imipenem and metronidazole, whereas
penicillin G, piperacillin (even when combined with tazobactam), and
cefoxitin were devoid of significant antimicrobial activity against all
strains (Table 1). Most of the clinical
isolates were susceptible to clindamycin and chloramphenicol.
Ciprofloxacin was also active against most of the strains tested. The
reproducibility of the MIC determinations was good, since, for the
three strains repeatedly tested, the MICs of each antimicrobial agent
were identical or varied only by a twofold dilution. The MICs obtained
for the control organisms varied by no more than 1 twofold dilution and were similar in range to the NCCLS reference values (7).
Regarding
-lactam susceptibility, all of the strains tested can be
distributed into three groups (Table
2). The first group is composed of
strains with the highest susceptibility to
-lactams (ATCC 27774, ATCC 29577, and D1). For these strains, amoxicillin, ticarcillin, and cefotaxime showed rather good antimicrobial activities. A second group,
comprising six isolates (D2 to D7), showed a positive nitrocefin test.
Against these strains, the inhibitory activities of amoxicillin and
ticarcillin were significantly lower than those observed against isolates belonging to the first group but were restored by clavulanate. This suggests production of at least a class A
-lactamase
(1). Among strains of the second group, the MICs of
cefotaxime ranged from 4 to 16 µg/ml. Neither clavulanate nor
sulbactam restored the activity of cefotaxime. Thus, the production of
an extended-spectrum
-lactamase cannot be excluded. The fact that
cloxacillin was unable to potentiate the activity of cefotaxime does
not favor the production of a class C
-lactamase. A third group,
comprising nine strains (D8 to D16), also resulted in high amoxicillin,
ticarcillin, and cefotaxime MICs compared to the first group. However,
for these strains the
-lactamase inhibitors were unable to enhance the activity of any antibiotic tested in combination.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
MICs of amoxicillin, ticarcillin, and cefotaxime, alone
and combined with -lactamase inhibitors, for 16 clinical
Desulfovibrio isolates, D. desulfuricans ATCC
27774, and D. desulfuricans ATCC 29577
|
|
Although the incidence of human infections caused by
Desulfovibrio spp. is unknown, these organisms are potential
pathogens for humans and should be taken into account for empirical
antibiotic therapy. Desulfovibrio spp. can be resistant to
various antimicrobial agents, including drugs commonly used to treat
mixed infections, such as
-lactams combined with
-lactamase
inhibitors, cefotetan, and cefoxitin. However, none of the strains
tested were resistant to imipenem or metronidazole; these should
therefore be considered the drugs most suitable for treating infections
caused by Desulfovibrio spp. Finally, it appears that a
class A
-lactamase may be involved in the resistance of some
strains to
-lactams; however, for other
-lactam-resistant strains
the mechanism of resistance is obviously more complex and remains to be determined.
 |
ACKNOWLEDGMENTS |
We thank Françoise Munier, Martine Benzaïed, and
Isabelle Scholtus for technical assistance.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratoire de
Bactériologie, Hôpital Central, 29 Avenue du Maréchal
de Lattre de Tassigny, 54035 Nancy Cedex, France. Phone: (33)
3.83.85.14.34. Fax: (33) 3.83.85.26.73. E-mail:
f.mory{at}chu-nancy.fr.
 |
REFERENCES |
| 1.
|
Ambler, R. P.,
A. F. Coulson,
J. M. Frere,
J. M. Ghuysen,
B. Joris,
M. Forsman,
R. C. Levesque,
G. Tiraby, and S. G. Waley.
1991.
A standard numbering scheme for the class A -lactamases.
Biochem. J.
276:269-270.
|
| 2.
|
Appelbaum, P. C.,
S. K. Spangler, and M. R. Jacobs.
1990.
Evaluation of two methods for rapid testing for -lactamase production in Bacteroides and Fusobacterium.
Eur. J. Clin. Microbiol. Infect. Dis.
1:47-50.
|
| 3.
|
La Scola, B., and D. Raoult.
1999.
Third isolate of a Desulfovibrio sp. identical to the provisionally named Desulfovibrio fairfieldensis.
J. Clin. Microbiol.
37:3076-3077[Abstract/Free Full Text].
|
| 4.
|
Loubinoux, J.,
F. Mory,
I. A. C Pereira, and A. Le Faou.
2000.
Bacteremia caused by a strain of Desulfovibrio related to the provisionally named Desulfovibrio fairfieldensis.
J. Clin. Microbiol.
38:931-934[Abstract/Free Full Text].
|
| 5.
|
Lozniewski, A.,
P. Maurer,
H. Schuhmacher,
J. P. Carlier, and F. Mory.
1999.
First isolation of Desulfovibrio sp. from a brain abscess.
Eur. J. Clin. Microbiol. Infect. Dis.
18:602-603[CrossRef][Medline].
|
| 6.
|
McDougall, R.,
J. Robson,
D. Paterson, and W. Tee.
1997.
Bacteremia caused by a recently described novel Desulfovibrio species.
J. Clin. Microbiol.
35:1805-1808[Abstract].
|
| 7.
|
National Committee for Clinical Laboratory Standards.
1997.
Methods for antimicrobial susceptibility testing of anaerobic bacteria, 4th ed. Approved standard. NCCLS document M11-A4.
National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 8.
|
Porschen, R. K., and P. Chan.
1977.
Anaerobic vibrio-like organisms cultured from blood: Desulfovibrio desulfuricans and Succinivibrio species.
J. Clin. Microbiol.
5:444-447[Abstract/Free Full Text].
|
| 9.
|
Tee, W.,
M. Dyall-Smith,
W. Woods, and D. Eisen.
1996.
Probable new species of Desulfovibrio isolated from a pyogenic liver abscess.
J. Clin. Microbiol.
34:1760-1764[Abstract].
|
Antimicrobial Agents and Chemotherapy, October 2001, p. 2933-2935, Vol. 45, No. 10
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.10.2933-2935.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Warren, Y. A., Citron, D. M., Merriam, C. V., Goldstein, E. J. C.
(2005). Biochemical Differentiation and Comparison of Desulfovibrio Species and Other Phenotypically Similar Genera. J. Clin. Microbiol.
43: 4041-4045
[Abstract]
[Full Text]
-
Goldstein, E. J. C., Citron, D. M., Peraino, V. A., Cross, S. A.
(2003). Desulfovibrio desulfuricans Bacteremia and Review of Human Desulfovibrio Infections. J. Clin. Microbiol.
41: 2752-2754
[Abstract]
[Full Text]
-
Morin, A.-S., Poirel, L., Mory, F., Labia, R., Nordmann, P.
(2002). Biochemical-Genetic Analysis and Distribution of DES-1, an Ambler Class A Extended-Spectrum {beta}-Lactamase from Desulfovibrio desulfuricans. Antimicrob. Agents Chemother.
46: 3215-3222
[Abstract]
[Full Text]